Hospital practice (1995)
-
Hospital practice (1995) · Feb 2011
Effect of adding nitroglycerin to early diuretic therapy on the morbidity and mortality of patients with chronic kidney disease presenting with acute decompensated heart failure.
Loop diuretics are considered first-line therapy for patients with acute decompensated heart failure (ADHF). Adding nitroglycerin (NTG) to diuretic therapy for alleviation of acute shortness of breath has been advocated in our institution. We evaluated the benefits of adding NTG to diuretics in the emergency department for patients with ADHF and chronic kidney disease (CKD). ⋯ There is a role for early administration of NTG in addition to diuretic therapy in patients admitted to the emergency department with ADHF, with resultant decreased length of stay and a trend toward a decrease in the composite endpoint of all-cause mortality and ADHF readmission. The mortality benefit at 2 years reported in our study is thought-provoking and raises a premise to be proven in randomized clinical trials.
-
Hospital practice (1995) · Feb 2011
Medical consultation and best practices for preoperative evaluation of elderly patients.
Preoperative evaluation of elderly patients is an important component of surgical practice in the 21st century. It can offer a comprehensive geriatric evaluation and be a key element in decreasing postoperative morbidity and mortality in this unique population group. Advanced surgical and anesthetic techniques have contributed to an increasing number of elderly and sicker geriatric patients undergoing surgery. ⋯ Advanced age increases the risk of developing complications post-surgery, but comorbidities are more important than age alone. General recommendations include avoiding drugs that increase the risk of delirium, ensuring appropriate hydration and calorie intake, minimizing bed rest, promoting ambulation, and early planning for discharge. Collaboration between surgeons and medical consultants aids in the identification of functional, cognitive, and nutritional deficits, provides structure for development and implementation of management plans, and promotes optimal patient outcome after surgical intervention in the elderly.
-
Hospital practice (1995) · Nov 2010
Comparative StudyEconomic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
The addition of glycoprotein IIb/IIIa inhibitors (GPIs) to heparin in percutaneous coronary intervention (PCI) procedures has been demonstrated to reduce ischemic complications; however, GPI use is known to increase the risk of bleeding events, which are linked to increased mortality, longer hospital length of stay, greater medical resource utilization, and increased costs. New antithrombotic therapies have the potential to improve clinical outcomes and decrease costs. The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) study of bivalirudin demonstrated significantly reduced clinical event rates (mortality and bleeding) compared with an unfractionated heparin (UFH)+GPI regimen. ⋯ Using a bivalirudin-based strategy in STEMI patients undergoing PPCI is associated with favorable clinical and economic outcomes when compared with an UFH+GPI-based strategy in a US hospital setting.
-
Hospital practice (1995) · Nov 2010
Review Meta AnalysisA review and meta-analysis of studies on the effect and timing of β-blocker administration in patients with ST-segment elevation myocardial infarction.
The utility of β-blockers during an evolving ST-segment elevation myocardial infarction (STEMI) has substantial theoretic physiological backing. This coupled with early successes using β-blockers in STEMI promulgated multiple guidelines expanding the use of this class of medication to all patients with acute coronary syndromes. However, recent studies have questioned the utility of β-blockers in the emergency department in these patients. The purpose of this article is to review the evidence behind the use of β-blockers in the emergency department for STEMI patients.
-
Hospital practice (1995) · Nov 2010
Emerging oral antiplatelet therapies for acute coronary syndromes.
Emergency department physicians, along with hospitalists and interventional cardiologists, provide first-line care for patients experiencing symptoms potentially associated with acute coronary syndromes (ACS). Because these health care providers encounter and manage patients with varying degrees of risk, a clear understanding of the modes of action, benefits, and limitations of various therapeutic options is crucial for achieving optimal outcomes in the acute-care setting. Oral antiplatelet therapy has a major role in the acute care of patients with suspected ACS due to the critical role of platelets in the pathophysiology of disease. ⋯ Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial. Results of phase 2 trials with PAR-1 antagonists suggest that these agents may provide incremental reduction in ischemic events without a bleeding liability. This hypothesis is being evaluated in 2 large ongoing phase 3 trials with vorapaxar, including the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial in patients with non-ST-segment elevation ACS.